Overview Financials News + Filings
|
| In millions, except per share items | Sep-30-20 | Jun-30-20 | Mar-31-20 | Dec-31-19 | Sep-30-19 | Jun-30-19 | Mar-31-19 | Dec-31-18 |
| | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Revenues: |
| Billing Services | 1.4 | 1.8 | 2.3 | 2.8 | 3.1 | 3.5 | 4.3 | 4.9 |
| OTC and Prescription Medicine | 0.3 | 0.4 | 0.5 | 0.7 | 0.8 | 0.9 | 1.1 | 1.4 |
| Total revenues | 1.8 | 2.3 | 2.8 | 3.5 | 3.9 | 4.4 | 5.4 | 6.3 |
| Revenue growth [+] | -54.4% | -48.9% | -48.1% | -44.8% | -46.2% | -24.6% | 35.9% | 206.2% |
| Billing Services | -53.9% | -47.9% | -47.2% | -43.4% | | | | |
| OTC and Prescription Medicine | -56.2% | -53.0% | -51.5% | -50.1% | | | | |
| Cost of goods sold | 0.2 | 0.3 | 0.4 | 0.5 | 0.6 | 0.7 | 0.8 | 1.0 |
| Gross profit | 1.5 | 2.0 | 2.4 | 3.0 | 3.3 | 3.8 | 4.6 | 5.3 |
| Gross margin | 87.0% | 87.0% | 86.7% | 85.9% | 84.8% | 84.8% | 84.9% | 83.7% |
| Selling, general and administrative [+] | 1.4 | 1.6 | 1.8 | 2.0 | 2.0 | 2.5 | 2.9 | 3.3 |
| General and administrative | 1.4 | 1.6 | 1.8 | 2.0 | 2.0 | 2.5 | 2.9 | 3.3 |
| Other operating expenses | 0.4 | 1.5 | 1.5 | 1.5 | 1.9 | 0.7 | 0.7 | 0.7 |
| EBITDA [+] | 0.1 | -0.7 | -0.4 | -0.1 | -0.1 | 1.0 | 1.4 | 1.7 |
| EBITDA growth | -225.9% | -163.2% | -129.1% | -104.0% | -106.3% | -26.5% | 88.0% | 847.7% |
| EBITDA margin | 7.9% | -29.1% | -14.9% | -1.9% | -2.9% | 23.5% | 26.6% | 26.8% |
| Depreciation | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBITA | 0.1 | -0.7 | -0.4 | -0.1 | -0.1 | 1.0 | 1.4 | 1.7 |
| EBITA margin | 7.4% | -29.5% | -15.3% | -2.2% | -3.1% | 23.3% | 26.4% | 26.6% |
| Amortization of intangibles | 0.4 | 0.4 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 |
| EBIT [+] | -0.2 | -1.1 | -0.8 | -0.5 | -0.6 | 0.6 | 1.0 | 1.2 |
| EBIT growth | -59.9% | -286.5% | -187.7% | -142.8% | -145.3% | -46.6% | 82.7% | 1997.2% |
| EBIT margin | -13.2% | -46.7% | -30.1% | -14.9% | -15.0% | 12.8% | 17.8% | 19.2% |
| Interest expense | 1.7 | 1.7 | 1.6 | 1.4 | 2.0 | 1.9 | 1.8 | 1.8 |
| Interest expense | 1.7 | 1.7 | 1.6 | 1.4 | 2.0 | 1.9 | 1.8 | 1.8 |
| Other non-ooperating expenses | 1.7 | 1.7 | 1.6 | 1.4 | 2.0 | 1.9 | 1.8 | 1.8 |
| Pre-tax income | -2.0 | -2.7 | -2.4 | -1.9 | -2.6 | -1.3 | -0.8 | -0.6 |
| Income taxes | -0.5 | -0.7 | -0.7 | -0.5 | -0.5 | -0.1 | 0.0 | 0.1 |
| Tax rate | 27.0% | 27.0% | 27.0% | 27.0% | 17.9% | 9.5% | -0.8% | -11.5% |
| Net income | -1.4 | -2.0 | -1.8 | -1.4 | -2.1 | -1.2 | -0.8 | -0.7 |
| Net margin | -81.0% | -87.6% | -62.8% | -39.9% | -54.0% | -26.9% | -15.5% | -10.6% |
| |
| Basic EPS [+] | ($0.06) | ($0.09) | ($0.08) | ($0.06) | ($0.09) | ($0.05) | ($0.04) | ($0.03) |
| Growth | -31.5% | 66.3% | 110.5% | 107.4% | -273.6% | -233.4% | -218.7% | -220.3% |
| Diluted EPS [+] | ($0.06) | ($0.09) | ($0.08) | ($0.06) | ($0.09) | ($0.05) | ($0.04) | ($0.03) |
| Growth | -31.5% | 66.3% | 110.5% | 107.4% | -273.6% | -233.4% | -218.7% | -220.3% |
| |
| Shares outstanding (basic) [+] | 22.9 | 22.9 | 22.9 | 22.9 | 22.9 | 22.9 | 22.9 | 22.9 |
| Growth | 0.0% | 0.0% | 0.0% | 0.0% | 4.5% | 11.2% | 18.9% | 27.7% |
| Shares outstanding (diluted) [+] | 22.9 | 22.9 | 22.9 | 22.9 | 22.9 | 22.9 | 22.9 | 22.9 |
| Growth | 0.0% | 0.0% | 0.0% | 0.0% | 4.5% | 11.2% | 18.9% | 27.7% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|